Duality Advisers LP Buys 7,068 Shares of Humana Inc. (NYSE:HUM)

Duality Advisers LP raised its holdings in Humana Inc. (NYSE:HUM) by 58.3% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 19,182 shares of the insurance provider’s stock after acquiring an additional 7,068 shares during the period. Humana accounts for 0.7% of Duality Advisers LP’s portfolio, making the stock its 15th largest position. Duality Advisers LP’s holdings in Humana were worth $6,651,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Leith Wheeler Investment Counsel Ltd. acquired a new stake in Humana in the 1st quarter valued at approximately $12,607,000. Ballast Inc. acquired a new stake in shares of Humana during the 1st quarter worth approximately $666,000. Mawer Investment Management Ltd. grew its holdings in shares of Humana by 100.4% during the 1st quarter. Mawer Investment Management Ltd. now owns 24,089 shares of the insurance provider’s stock worth $8,352,000 after purchasing an additional 12,066 shares in the last quarter. Buck Wealth Strategies LLC acquired a new stake in shares of Humana during the 1st quarter worth approximately $1,871,000. Finally, Mediolanum International Funds Ltd acquired a new stake in shares of Humana during the 1st quarter worth approximately $13,000,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Up 0.9 %

Shares of HUM traded up $3.27 during mid-day trading on Friday, hitting $383.00. 444,248 shares of the company’s stock were exchanged, compared to its average volume of 1,767,927. The company has a market cap of $46.15 billion, a PE ratio of 23.64, a P/E/G ratio of 2.19 and a beta of 0.51. Humana Inc. has a 52 week low of $298.61 and a 52 week high of $530.54. The company has a 50-day simple moving average of $354.15 and a 200 day simple moving average of $347.04. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.67.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, topping the consensus estimate of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The company had revenue of $29.61 billion during the quarter, compared to analysts’ expectations of $28.52 billion. During the same period last year, the business earned $9.38 EPS. The business’s quarterly revenue was up 10.7% on a year-over-year basis. On average, research analysts forecast that Humana Inc. will post 16.27 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be paid a $0.885 dividend. The ex-dividend date is Friday, June 28th. This represents a $3.54 annualized dividend and a dividend yield of 0.92%. Humana’s dividend payout ratio is presently 22.04%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on HUM. Cantor Fitzgerald reissued a “neutral” rating and set a $360.00 price objective on shares of Humana in a report on Wednesday, June 12th. UBS Group decreased their price target on Humana from $334.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday, April 25th. Piper Sandler began coverage on Humana in a research note on Wednesday, June 26th. They issued an “overweight” rating and a $392.00 price target on the stock. Barclays decreased their price target on Humana from $356.00 to $310.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 2nd. Finally, Wells Fargo & Company decreased their price target on Humana from $413.00 to $350.00 and set an “overweight” rating on the stock in a research note on Monday, April 8th. Fourteen investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $409.55.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.